NHS changes reshape route from drugs to patients
The September issue of the brief highlights how changes in the NHS and primary care are reshaping the path from pharmaceutical innovation to patient treatment.
Contributors Chloe Williams and Sarah Ellson of Fieldfisher examine the core question: how to turn promising science into NHS-approved therapy.
Innovative medicines must clear regulatory hurdles, health-technology assessments and funding decisions before they reach clinicians.
The “ Five Facts ” segment outlines how the health service and primary-care environment is altering that route.
A Q&A funded by Gilead Sciences features its UK and Ireland Vice President Peter Wickersham, stressing the need to place community voices at the centre of access.
Dr Richard Graham of TruTechnologies warns that insufficient focus on trial execution, sample integrity, patient instructions and unresolved queries, creates enrolment protection challenges.
According to Dr Anton Yuryev, Consulting Director of Bioinformatics and Data Science at Elsevier, AI adds a new dimension to data handling and decision-making in the innovation pipeline.
Read Also: Liverpool launches lab for disease drug discovery
Adam Green of Mettler Toledo explains that factory x-ray inspection helps guarantee quality in pharmaceutical and medical-device production.
Gita Mendis of ZPB Associates discusses how partnerships drove her firm’s win in the EHP Awards Partnership Project of the Year (Pharmaceuticals) category.
In the news round-up, NHS Scotland launches neonatal initiatives aimed at improving newborn health outcomes.
Officials cite a £240 million “paper mountain” that the Single Patient Record digitalisation programme is intended to reduce.
Leicester Hospital Trust secures a five-year contract to deliver England’s new Healthy Living service for diabetes patients.
Recent appointments include four new specialists joining Made Smarter in the North West, and Matthew Dallas becoming CFO of Syntis Bio. Tiffany J Vora joins Simris Group as Strategic Advisor following Andreas Pahl’s appointment as CEO of Simris Biologics.
The brief returns with a focus on practical steps that move innovation from lab to the bedside of the health service, and the next issue is slated for early October.
